Consolidatedstandalone figures are read separately and never mixed into these tables
In thirty seconds
Worth watching
0 serious2 watch5 findings
Cipla Limited presents a high-quality global pharmaceutical profile anchored by market-leading respiratory franchises, One India branded dominance, and a net cash balance sheet of ₹9,494.00 crore. While Q1 FY2027 reported revenue growth (2%) and EBITDA margin (16.7%) appear subdued due to marketing spend accounting reclassifications, Middle East freight inflation, and front-loaded US launch expenses, the medium-term thesis remains intact. Growth will be catalyzed by scaling generic Ventolin, commercializing three complex respiratory filings and peptides in North America, and expanding anti-obesity GLP-1/GIP therapies (Yurpeak) in India.
Contested NPPA DPCO overcharging demand notices total ₹2,011.00 crore.₹2,011.00 crore aggregate demand (₹863.00 crore principal + ₹1,148.00 crore interest); ₹202.15 crore deposited under protest/Court orders.
Contested Income Tax reassessment demands total ₹499.45 crore gross.Disputed income tax demands total ₹499.45 crore with ₹306.13 crore paid under protest following February 2023 Survey/Search action.
Middle East war logistics and freight inflation impacting Q1 costs by 1-2% of revenue.Geopolitical conflict in Middle East creating transient cost inflation of 100-200 bps on operating revenue.
The number that misleads
Cipla Limited's headline Q1 FY2027 revenue growth of 2% (₹7,119.00 crore) and EBITDA margin dip to 16.7% mislead retail investors into perceiving operational stagnation. In reality, effective April 1, 2026, an accounting reclassification reduced reported top-line revenue by subtracting certain marketing expenditures (underlying revenue growth was ~4%).
Cipla Limited is a global pharmaceutical company focused on respiratory care, complex generics, anti-retrovirals, urology, cardiology, and consumer wellness. It operates an integrated business across One-India (branded formulation, trade generics, consumer health), North America (generic and complex respiratory/peptide formulations), One Africa (South Africa private/tender markets), and EMEU/Rest of World, backed by AI-enabled manufacturing and R&D.
How the money is actually made
Revenue is driven by branded prescription sales in India (39% of FY2026 revenue) and South Africa, complex generic and specialty respiratory/peptide sales in North America (45% of revenue), active pharmaceutical ingredients (APIs), OTC consumer health products, and licensing/royalty arrangements.
Segment economics
FY2026 · ₹ cr
Revenue share shows where the sales are. PBIT margin shows where the
profit is — and the two rarely match.
SegmentRevenueSharePBITMarginCapital
Pharmaceuticals 28,163100%5,55419.7%42,496
Where the edge is
Global leadership in respiratory inhaler technology and complex generics, deep distribution in One-India, strong brand equity across chronic therapies, and net cash positive balance sheet.
Operating KPIs — the physical business behind the numbers (5)
Consolidated Revenue from Operations28163.00FY2026 4070b137-2a68-4790-8821-268ff7c4e408.pdf · p.22
Screener puts these behind a paywall. They are disclosed in the
annual report and investor presentation, so they are free here, with the source printed.
The read
Cipla Limited presents a high-quality global pharmaceutical profile anchored by market-leading respiratory franchises, One India branded dominance, and a net cash balance sheet of ₹9,494.00 crore. While Q1 FY2027 reported revenue growth (2%) and EBITDA margin (16.7%) appear subdued due to marketing spend accounting reclassifications, Middle East freight inflation, and front-loaded US launch expenses, the medium-term thesis remains intact. Growth will be catalyzed by scaling generic Ventolin, commercializing three complex respiratory filings and peptides in North America, and expanding anti-obesity GLP-1/GIP therapies (Yurpeak) in India.
Why the headline number misleads here
Cipla Limited's headline Q1 FY2027 revenue growth of 2% (₹7,119.00 crore) and EBITDA margin dip to 16.7% mislead retail investors into perceiving operational stagnation. In reality, effective April 1, 2026, an accounting reclassification reduced reported top-line revenue by subtracting certain marketing expenditures (underlying revenue growth was ~4%). Furthermore, reported margins are temporarily compressed by front-loaded operating costs for pending US product launches, 1-2% Middle East war cost inflation, and delayed PLI incentive accruals. Investors should focus on the underlying pipeline execution—specifically generic Ventolin scale-up, three major complex respiratory filings, and anti-obesity GLP-1/GIP traction (Yurpeak)—which underpins management's line of sight toward a $1 billion US exit run-rate and 18.5-20.0% FY2027 EBITDA margins.
What matters most
Timely US FDA approval and commercial launch execution for the three major complex respiratory filings and complex peptide product.
What would change the picture
Adverse regulatory inspection outcomes/Warning Letters at manufacturing sites or negative judicial verdicts on NPPA DPCO overcharging demands totaling ₹2,011.00 crore.
Trading at 32.7x against its own 10-year median of
29.2x —
0.4σ above
its usual range. This compares the company with its own history, not with other companies.
1Bonus 3:22006-04
Numbered markers are corporate actions and, once the filings are read, capital and governance events. Prices are split-adjusted so the series is continuous.
What you must understand
warnContested NPPA DPCO overcharging demand notices total ₹2,011.00 crore.
Represents a substantial contingent legal claim pending before judicial courts.
Strong growth outlook for high-margin US specialty business.
What doesn't add upread against itself
Two kinds of item, both taken from the company's own documents: figures that disagree with other figures in the same filing, and disclosures that sit in the notes rather than the statements. Neither is an allegation — each is a question the filing raises about itself.
Buried in the notes
Income tax reassessment demands of ₹499.45 crore following search/survey action in February 2023.
Reassessment orders issued for AY2015-16 to AY2023-24; ₹306.13 crore paid under protest.
Substantial tax demand under dispute following tax authority survey.
What the numbers mean when read together — computed from the filings, not a score.
Net margin compressing
Net margin has narrowed from 16.1% to 11.8% year-on-year — profitability per rupee of sales is shrinking.
Why this reading: Noted with caution — worth watching, but not yet conclusive on its own. Business has ups and downs; one soft reading is not a verdict.
Full read
Quarter net margin 11.8% vs 16.1% four quarters earlier. Sustained compression signals pricing pressure, cost inflation, or mix deterioration.
Capital work-in-progress is sticky
Capital work-in-progress has stayed high (16% of fixed assets) without converting to productive assets — worth checking whether projects are genuinely progressing.
Why this reading: Noted with caution — worth watching, but not yet conclusive on its own. Business has ups and downs; one soft reading is not a verdict.
Full read
CWIP ₹2,042 cr vs ₹1,153 cr two years earlier, against fixed assets ₹12,434 cr. Perennial CWIP that never becomes a fixed asset can hide stalled projects or capitalised costs that should have been expensed.
Operating cash flow backs the profit
Operating cash is 107% of trailing profit — the earnings are converting to real cash, not just accruals.
Why this reading: A positive signal: cash conversion at or above ~0.9 means reported profit is showing up as actual cash.
Full read
Operating cash ₹4,134 cr against trailing net profit ₹3,862 cr. Consistent conversion near or above 1.0 is a hallmark of genuine earnings.
Generates free cash
Free cash flow is positive and consistent — the business funds itself after capex.
Why this reading: A positive signal in the numbers, shown for balance alongside the concerns.
Full read
Latest free cash flow ₹928 cr. Negative in only 0 of 12 years. A self-funding business needs less external capital and dilutes less.
Deleveraging
Borrowings have fallen 54% over two years — the balance sheet is getting lighter.
Why this reading: A positive signal in the numbers, shown for balance alongside the concerns.
Full read
Borrowings down to ₹258 cr from ₹560 cr. Falling debt reduces finance cost and financial risk.
What they promised, and what happened
Operating EBITDA Margin
Said18.50-20.00 percent Ashish Adukia, 2026-07-23
Happened16.70 percent
Too early
On the record, not yet due
Operating EBITDA Margin18.50-20.00 percentAshish Adukia · 2026-07-23 · by FY2027
US Business Exit Run RateUSD 1000.00 million (~$1 billion)Achin Gupta · 2026-07-23 · by Q4 FY2027
Every line is dated and attributed, so the next results can be checked against it.
Reading the annual report
Where they say they are going
Scaling complex respiratory filings (three significant respiratory launches plus generic Ventolin ramp-up), expanding peptide filings (including generic Saxenda/Liraglutide), commercializing tirzepatide (Yurpeak) in India, advancing AI-enabled manufacturing/lab automation, and targeting a $1 billion exit run-rate in North America.
What they promised before, and what happened
In FY2026, global revenue reached ₹28,163.00 crore against ₹27,548.00 crore in FY2025. EBITDA reached ₹5,925.00 crore (21.00% margin). Launched 166 products globally, holding 285 cumulative ANDA and NDA filings as of March 31, 2026.
Where the money actually went
Prioritizes R&D (7.00% of revenues; ₹1,974.00 crore in FY2026), organic capex for biosimilar/respiratory manufacturing infrastructure, dividend distributions (board policy up to 30% of consolidated PAT; final dividend of ₹13/share proposed for FY2026), and targeted M&A for differentiated assets while maintaining a net cash positive balance sheet (~₹9,494.00 crore net cash).
What they are becoming less dependent on
Expanding presence in chronic care (respiratory, GLP-1/GIP anti-obesity, diabetes, oncology), consumer wellness via Cipla Health, and deep-market expansion in Europe and emerging markets while shifting North America from simple oral solids to complex inhalers and peptides.
The part most readers miss
Headline Q1 FY2027 margin dips (~16.7% EBITDA margin) reflect front-loaded launch expenditures for upcoming US launches, transient Middle East war-related freight/cost inflation (1-2% of revenue), accounting reclassifications of marketing spend as revenue reductions, and lower foreign exchange/PLI timing rather than underlying operational deterioration.
Forensic modelscomputed from the filed statements
Every score below is calculated here from the reported numbers — none of it is asserted. Open the notebook at the foot of the section to see each formula with this company's figures in it.
Altman Z″
13.93Safe
Distress model for emerging markets. Above 2.6 is safe, below 1.1 is the distress zone.
What is this, and how do I read it?
Altman Z″ — distress model — Edward Altman, NYU, 1968; the Z″ variant was published in 1995 for emerging markets and non-manufacturers.
A single score built from four balance-sheet ratios that, together, separated companies that later went bankrupt from those that did not. Altman tested it on manufacturers; the Z″ version drops the sales-to-assets term, which made industrial firms look better than service businesses.
X1 · Working capital ÷ total assets
Short-term liquidity. Negative means current liabilities exceed current assets — the company owes more within a year than it holds.
X2 · Retained earnings ÷ total assets
Cumulative profitability. A young or serially loss-making company scores low here regardless of this year.
X3 · EBIT ÷ total assets
Operating productivity of the asset base, before financing and tax.
X4 · Net worth ÷ total liabilities
How far assets can fall before liabilities exceed them.
How to read itAbove 2.6 is the safe zone. Between 1.1 and 2.6 is grey. Below 1.1 is the distress zone. The score is a screen, not a prediction — it tells you which balance sheets deserve a second look.
Where it failsNot meaningful for banks, NBFCs or insurers, whose balance sheets are structurally different. Also unreliable for asset-light businesses, which carry few assets by design, and for holding companies whose value sits in unconsolidated stakes.
Piotroski F
3 / 9
Profitable this year
Operating cash positive
Return on assets improved
Cash exceeds profit
Leverage reduced
Liquidity improved
No share dilution
Margin improved
Assets working harder
What is this, and how do I read it?
Piotroski F-Score — fundamental momentum — Joseph Piotroski, University of Chicago, 2000, in a study of whether accounting signals could improve returns among cheap stocks.
Nine yes-or-no tests across profitability, leverage and operating efficiency. Each pass scores one. It asks a narrow question: is this business getting better or worse on its own terms, year over year?
Profitability (4 tests)
Positive profit, positive operating cash, improving return on assets, and cash exceeding profit. The last is the quality test — profit that outruns cash is the one to question.
Leverage and liquidity (3 tests)
Falling debt, improving current ratio, no new shares issued. Growth funded by dilution scores zero here.
Operating efficiency (2 tests)
Improving margin and improving asset turnover.
How to read it7 or more suggests improving fundamentals; 3 or fewer suggests deterioration. It measures direction, not quality — a weak company improving can score higher than a strong one holding steady.
Where it failsA single year of comparison, so one unusual year distorts it. Says nothing about valuation, competitive position or management. Piotroski designed it to rank already-cheap stocks, not to judge a company in isolation.
Beneish M-Score — earnings manipulation — Messod Beneish, Indiana University, 1999. Best known for the Cornell students who flagged Enron with it a year before the collapse.
Eight ratios comparing this year with last, weighted into one score. It does not detect fraud. It detects the accounting patterns that tend to accompany managed earnings — receivables outrunning sales, margins falling while the business grows, assets shifting into categories that are harder to verify.
DSRI · Days Sales in Receivables Index
Receivables against sales, this year versus last. Above 1 means the company is collecting more slowly — sales may be being recognised before cash is likely.
GMI · Gross Margin Index
Last year's margin divided by this year's. Above 1 means margins deteriorated, which raises the incentive to manage the numbers.
AQI · Asset Quality Index
The share of assets that are neither current nor fixed — intangibles, deferred costs, "other". Above 1 means more of the balance sheet has moved into items whose value rests on judgement.
SGI · Sales Growth Index
Growth itself is not manipulation, but fast-growing companies face more pressure to sustain the trajectory.
DEPI · Depreciation Index
Above 1 means the depreciation rate slowed — assets are being written off more slowly, which flatters profit.
SGAI · Selling, General & Administrative Index
Overheads against sales. A disproportionate rise signals loss of control.
LVGI · Leverage Index
Rising leverage increases the pressure to meet covenants.
TATA · Total Accruals to Total Assets
The heaviest weight in the model. Profit not backed by cash, scaled by assets.
How to read itAbove −1.78 is the threshold at which the model classifies a company as a likely manipulator. That threshold produces false positives — fast growers and companies mid-acquisition often cross it innocently. Treat it as a prompt to read the notes, never as an accusation.
Where it failsNeeds two comparable years. Meaningless after a large acquisition, demerger or accounting-standard change, when the year-over-year ratios compare different businesses. Not applicable to banks or insurers.
Cash vs profit
1.21×12-year cumulative
Accruals are -0.7% of assets. Free cash flow negative in 0 of 12 years.
DuPont — return on equity FY2026
Net margin13.7%×Asset turnover0.66××Leverage1.23×=ROE11.2%
What is this, and how do I read it?
DuPont decomposition — Devised inside the DuPont Corporation in the 1920s and still the standard way to read a return on equity.
Splits return on equity into its three sources, so the same headline number can be traced to very different businesses.
Net margin
What the company keeps from each rupee of sales. High margin points to pricing power or a genuine cost advantage.
Asset turnover
Sales generated per rupee of assets. High turnover points to efficiency — a retailer earns this way, a utility never will.
Leverage (equity multiplier)
Assets divided by equity. This multiplies whatever the first two produce, in both directions.
How to read itA 20% ROE built on margin and turnover is a different proposition from a 20% ROE built on 3× leverage. The first survives a downturn; the second amplifies it.
Where it failsA single year. Negative equity makes it meaningless. Leverage is structural for lenders, so the third term carries no signal there.
Leverage & coverage FY2026
Debt / equity0.01×
Interest coverage102.11×
Net debt / EBITDA-0.13×
ROCE15.0%
Capital that builds FY2023 → FY2026
Capital deployed+41%
Revenue produced+24%
Still in CWIP₹2,042 cr
Capital and revenue are growing at broadly similar rates — the asset base is being used, not just added to.
The formula notebook — every number above, worked out
Cash vs profitcumulative operating cash flow ÷ cumulative net profit₹35,110 cr ÷ ₹29,110 cr, over 12 years1.21×Above 1.0 means cash exceeds reported profit — the healthier reading.
Accruals (Sloan)(net profit − operating cash flow) ÷ average total assets(₹3,862 − ₹4,134) cr ÷ average assets-0.7%Negative means cash exceeded profit — the healthier reading. Positive above ~10% is where accruals start to dominate earnings.
DuPont — return on equitynet margin × asset turnover × leverage13.7% × 0.66 × 1.2311.2%Splits ROE into whether returns come from operations or from borrowing.
Beneish M — earnings manipulation−4.84 + 0.920·DSRI + 0.528·GMI + 0.404·AQI + 0.892·SGI + 0.115·DEPI − 0.172·SGAI + 4.679·TATA − 0.327·LVGIDSRI 0.998 · GMI 1.239 · AQI 1.26 · SGI 1.022 · DEPI 1.122 · SGAI 1.076 · TATA -0.006 · LVGI 1.147-2.31Above −1.78 is the threshold at which the model flags a company as a likely manipulator.
Interest coverageEBIT ÷ finance cost₹5,554 cr ÷ ₹54 cr102.11×How many times operating profit covers the interest bill.
Debt to equityborrowings ÷ net worth₹258 cr ÷ ₹34,432 cr0.01×Read against the sector — infrastructure carries more than software.
Capital that buildsgrowth in fixed assets + CWIP, against growth in revenuecapital +41% vs revenue +24%, FY2023 to FY202617pp gapMoney going in far faster than revenue coming out. For an incubator this is expected — the test is whether it eventually converts.
Going deepersame statements, harder questions
Montier C-Score
3 / 6flags raised
Profit and cash flow diverging
Receivables growing faster than sales
Inventory building against sales
Other assets rising as a share of the balance sheet
Depreciation falling against fixed assets
Assets growing unusually fast
Six conditions that tend to appear together when earnings are being managed. A flag is a question, not a verdict.
What is this, and how do I read it?
Montier C-Score — the cooking score — James Montier, then at Dresdner Kleinwort, 2008, as a deliberately simpler companion to Beneish.
Six binary flags, each a condition that appears when earnings are being flattered. Montier's argument was that you do not need a weighted regression — the conditions tend to cluster, and counting them is enough.
Profit and cash diverging
Net income growing faster than operating cash flow. The single most reliable warning in accounting.
Receivables growing faster than sales
Revenue recognised ahead of collection.
Inventory building against sales
Production outrunning demand, with the write-down still to come.
Other assets rising as a share of the balance sheet
Value migrating into items that are difficult to verify.
Depreciation slowing against fixed assets
Useful lives extended, which lifts reported profit without any operating change.
Assets growing unusually fast
Above roughly 25% a year, often through acquisition, which resets the comparative base and obscures the underlying trend.
How to read it4 or more flags warrants a careful read of the notes. 0 or 1 is unremarkable. Each flag is a question — several together are a pattern.
Where it failsA company mid-expansion trips several flags legitimately: inventory builds ahead of a launch, assets grow with a new plant. Read alongside what the business is actually doing.
Return on invested capital FY2026
ROIC12.4%
On new capital since FY202311.1%
Capital employed₹33,672 cr
NOPAT over equity plus debt less cash, at a notional 25% tax. Incremental ROIC is the return on money put in since then — the number that decides whether growth creates value or consumes it.
What is this, and how do I read it?
Return on invested capital, and incremental ROIC — Standard in corporate finance; the incremental form was popularised by Michael Mauboussin as the test of whether growth creates value.
ROIC measures what the business earns on all the capital it employs — equity plus debt, less cash. Incremental ROIC asks a sharper question: what has it earned on the money put in since a chosen year?
NOPAT
Operating profit after a notional tax charge, so the figure is independent of how the company is financed. We use 25%.
Invested capital
Equity plus borrowings less cash — the money actually at work.
Incremental ROIC
Change in NOPAT divided by change in invested capital. If it sits below the cost of capital, growth is destroying value however fast revenue rises.
How to read itROIC comfortably above the cost of capital — call it 11–13% in India — means growth compounds. Below it, growth consumes. Incremental below headline means recent investment is earning less than the legacy business.
Where it failsDistorted in the year of a large acquisition. Understated for companies mid-build, where capital is deployed but capacity has not yet been commissioned — an incubator will look poor until it does not.
Earnings quality ladder FY2026
Cash ÷ EBITDA0.70×
Cash ÷ profit1.07×
Free cash ÷ profit0.24×
Read downward. Cash can cover EBITDA and still not survive capex — the third rung is where a capital-hungry business shows itself.
What is this, and how do I read it?
The earnings quality ladder — Not a named model — the standard sequence an analyst walks when testing whether reported profit is real.
Three ratios read in order, each stricter than the last.
Cash ÷ EBITDA
Does operating profit arrive as cash? Below 0.8 points to working capital absorbing it.
Cash ÷ profit
Does bottom-line profit arrive as cash? Below 1.0 persistently is the classic warning.
Free cash ÷ profit
Does anything survive capex? This is where capital-hungry businesses reveal themselves — a company can pass the first two and still never generate spendable cash.
How to read itRead downward. Each rung failing where the one above passed tells you exactly where the cash is going.
Where it failsA single year of heavy capex depresses the third rung legitimately. Judge it across a cycle.
What the price implies
33.6%free cash flow growth, every year for ten years
The growth rate that makes today's market value equal the discounted cash flows, at a 11.5% discount rate and 4.0% terminal growth. Not a forecast — the arithmetic of what is already in the price. Compare it with what the business has actually delivered.
What is this, and how do I read it?
Reverse DCF — the growth already in the price — A standard inversion of discounted cash flow, used to avoid the forecasting problem entirely.
Instead of forecasting cash flows and deriving a value, it takes today's market value as given and solves for the growth rate that would justify it. The output is not a view — it is the arithmetic of what the market is currently assuming.
Discount rate
The return required for the risk taken. We use 11.5%, roughly the long-run cost of equity in India.
Terminal growth
Growth beyond the explicit ten years. We use 4%, near long-run nominal GDP.
The output
The free-cash-flow growth rate, every year for a decade, that makes the discounted total equal today's market value.
How to read itCompare it with what the business has actually delivered. A price implying 30% a year against a decade of 15% is a demanding assumption; the reverse is a modest one.
Where it failsUseless when free cash flow is negative or unusually depressed, which is common mid-capex. Highly sensitive to the discount rate — a point either way moves the answer materially.
Reading the numbers on this pagetwo bases, both shown
Some figures appear twice on this page with different values. That is not an error — they sit on different bases. The live feed reports a rolling twelve months; everything computed here comes from the last audited statements. Both are shown so you can see which is which.
Return on equity
Trailing twelve months, live feed14.5%
FY2026, as filed11.2%
3.3% apart
Operating margin
Trailing twelve months, live feed13.3%
FY2026, as filed21.0%
7.8% apart
Where the two disagree, every model, screen and ratio computed on this page uses the filed figure, because the rest of the page is on that basis.
Published screening frameworksrules applied, not opinions quoted
Each framework below is a set of stated, mechanical criteria from published work, run against this company's own filed numbers. Passing or failing a screen is not a verdict — different frameworks disagree by design, and that disagreement is itself informative.
Graham — defensive investor
4 / 6
Current ratio above 2 3.44×
Debt below net worth ₹258 cr vs ₹34,432 cr
Positive earnings every year 12 of 12 years
Earnings growth over the period 52% since FY2022
P/E below 15 35.1×
P/E × P/B below 22.5 109.5
Benjamin Graham's stated criteria for a defensive stock, applied to the filed numbers. A company failing several is not disqualified — Graham designed these to be deliberately strict.
Greenblatt — magic formula
0 / 2
Return on capital above 20% 16.0%
Earnings yield above 8% 2.8%
Two ratios only: what the business earns on its capital, and what you pay for those earnings. Designed to be ranked across a universe rather than read in isolation.
O'Neil — CAN SLIM growth tests
0 / 4
Annual earnings growth above 25% -26%
Revenue growth above 20% 2%
Return on equity above 17% 11.2%
Share count not expanding equity capital ₹162 cr
The fundamental half of William O'Neil's framework. The market and leadership components are judgement calls and are not scored here.
Quality — compounder tests
4 / 4
Cash conversion above 0.9× 1.21× over 12 years
ROCE above 15% 15.0%
Interest covered more than 4× 102.11×
Debt below half of equity 0.01×
The characteristics long-term holders commonly look for: cash-backed earnings, high returns on capital, and debt that never forces a decision.
Against the sector48 companies
Median of the companies we hold in the same sector (Healthcare). Every figure on both sides is the live feed's trailing twelve months, so the two are measured the same way whatever depth of extraction this company has had. A number only means something next to something else — expensive against the market and cheap against peers are different facts.
P/E
35.1×
47.9×
-27%
P/B
3.1×
6.0×
-48%
Return on equity
14.5%
17.8%
-19%
Operating margin
13.3%
19.1%
-31%
Net margin
11.9%
15.7%
-24%
Dividend yield
1.0%
0.3%
+197%
this companysector median
The page in pictures
Where the revenue comes from
Segment share of revenue, FY2026.
Pharmaceuticals100.0%
Where the profit comes from
Segment PBIT, FY2026. Revenue share and profit share rarely match — that gap is the point.
Revenue and what it leaves behind
Bars are revenue; the line is net margin. Revenue rising while the line falls is the shape worth noticing.
Revenue (₹ cr)Net margin %
Where the year's cash went — FY2026
Operating cash first, then what the business spent and raised.
Quality over time
One year is a snapshot. These are the two lines that matter across a cycle.
Cash ÷ profit (×)ROCE (÷10)
Where cash gets stuck
Rising debtor or inventory days against flat sales is the earliest visible sign of stress.
Debtor daysInventory daysPayable daysCash cycle
Growth & valuation workspace
Set your own assumptions and watch the numbers move. A scenario calculator — the outputs are the arithmetic of your inputs.
User-driven scenario tool. Implied value and CAGR follow only from the assumptions you set — not a FinMinutes forecast, recommendation, or target price.
Valuation & quality
One canonical set of figures — the same numbers used everywhere else on this page and on the screener.
What you payHow the price compares with earnings, book and sales.
P/E (TTM)
35.1x
trailing 12m, live feed
P/B
3.12x
P/S
3.79x
PEG
2.79
Dividend yield
0.98%
What it earnsMargins and returns as the live feed reports them, on a rolling twelve months. The models above compute the same measures from the last audited statements, so the two can differ.
Operating margin
13.3%
trailing 12m, live feed
Net margin
11.9%
trailing 12m, live feed
Return on equity
14.5%
trailing 12m, live feed
How it is fundedLeverage and what is returned to shareholders.
Debt / equity
0.02
conservative
Payout ratio
31.2%
Book value / share
₹426.1
Return on equity of 11.2% is built on a 11.9% net margin and debt of 0.02x equity. The full DuPont breakdown sits in the forensic models above. Filed statements give 11.2%; the feed reports 14.5% on a trailing basis. The filed figure is used here because every other number on this page is on that basis.
Ownership & Skin in the Game
How the register has moved over recent quarters — the direction matters more than the level.
Promoter― 0.00
Sep '2529.21%
Dec '2529.21%
Mar '2629.21%
Jun '2629.21%
Promoter held steady from 29.21% to 29.21% across these quarters.
FII▼ 4.34
Sep '2524.54%
Dec '2523.93%
Mar '2622.55%
Jun '2620.20%
FII trimmed from 24.54% to 20.20% across these quarters.
MF▲ 0.33
Sep '2520.23%
Dec '2519.21%
Mar '2618.66%
Jun '2620.56%
MF rose from 20.23% to 20.56% across these quarters.
Other▲ 4.01
Sep '2526.02%
Dec '2527.65%
Mar '2629.58%
Jun '2630.03%
Other rose from 26.02% to 30.03% across these quarters.
Skin in the game
A holding percentage says who controls the company. This says whether the promoter has been putting money in or taking it out.
Money in₹0 cr
Money out₹118 cr
Net−₹118 cr
OUTDividend Payment Promoter Group (Dr. Y. K. Hamied & family holding 33.47%)FY2026₹118 cr promoter share of ₹351 cr paid · 33.47%
Named holders
HolderTypeStakePledgedAs of
Dr. Y. K. Hamied & Promoter GroupPromoter33.47%0.00%2026-03-31
Shares, tax and what was paid out
Per-share figures hide a share count that moved. Effective tax rate hides a one-off credit. Both sit here beside the payout, year by year, as the accounts state them.
Period
Shares (cr)
Effective tax
Dividend / share
Payout
What changed
FY2026
80.78
24.6%
₹13.00
27.1%
Face value ₹2 per share; total paid up share capital ₹161.56 crore (80,77,95,781 shares). Issued shares under ESOP options during the year. · Consolidated tax expense of ₹1,353.84 crore on PBT of ₹5,499.54 crore.
FY2025
—
—
₹13.00
19.9%
An effective rate far from the statutory band is usually a deferred-tax movement or a one-off credit, not a lower tax bill. The note beside it, where the filing gives one, says which.
Working capital12-year series
Where cash gets stuck. A rising inventory or debtor line against flat sales is the earliest sign of trouble in the numbers.
Measure
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Debtor days How long customers take to pay
93
83
66
57
65
68
73
73
Inventory days How long stock sits before it sells
250
267
232
230
228
217
231
252
Payable days How long the company takes to pay suppliers
123
139
103
108
112
102
116
123
Cash conversion cycle Debtor + inventory − payable days
220
211
195
180
181
182
188
202
Working capital days
132
113
94
95
113
120
128
106
ROCE % Return on capital employed
11.0%
12.0%
17.0%
17.0%
18.0%
23.0%
23.0%
15.0%
The debt wallFY2026
How much is owed answers one question. When it falls due answers a different one. This is the repayment ladder as the borrowings note states it, with instrument-level detail rolled into the buckets.
Within 1 year
₹141 cr54%
1 to 3 years
₹117 cr46%
3 to 5 years
—0%
Beyond 5 years
—0%
Total borrowings₹258 cr
Due within a year54%
Average cost6.71%
54% of borrowings fall due inside twelve months. That is a refinancing question, not a solvency one — read it beside cash and the operating cash flow for the same year.
Operating metrics disclosed in the business review and MD&A. These, not margins, are what the business is actually run on.
One India Revenue Share derived42.19percent
FY2026▲ 0.7 vs FY2025
Derived as One India revenue (11881.00 crore) / Total revenue (28162.59 crore) * 100
4070b137-2a68-4790-8821-268ff7c4e408.pdf · p.22
North America Revenue Share derived26.95percent
FY2026▼ 1.2 vs FY2025
Derived as North America revenue (7589.00 crore) / Total revenue (28162.59 crore) * 100
4070b137-2a68-4790-8821-268ff7c4e408.pdf · p.22
R&D Spend % of Revenue 7.00percent
FY2026▲ 1.4 vs FY2025
R&D expenditure as percentage of consolidated operating revenue
4070b137-2a68-4790-8821-268ff7c4e408.pdf · p.30
Cumulative ANDA and NDA Filings 285filings
FY2026
Cumulative active filings with US FDA
4070b137-2a68-4790-8821-268ff7c4e408.pdf · p.31
US FDA Inspection Observations 1observations
Jun 2026▲ 1.0 vs Q4 FY2026
Form 483 with 1 observation issued at InvaGen NY facility in July 2026
a036a014-e0e9-4194-9a9e-9d44134da589.pdf · p.4
Read using the Pharmaceuticals framework(from the listed sector). Primary valuation lens: P/E excluding one-time exclusivity gains.
Read more closely in this sector: Status of each US-filed plant · Price erosion stated · One-product dependence.
Trends
The shape of the business over time (annual) — read the direction, not the single print.
Revenue (₹ cr)
Net profit (₹ cr)
EBITDA margin (%)
Annual Profit & Loss ₹ cr
Line
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue from operations
19,160
21,763
22,753
25,774
27,548
28,163
Other income
266
99
293
552
862
882
EBITDA
—
—
—
6,291
7,128
5,925
Depreciation
1,068
1,052
1,172
1,051
1,107
1,211
Finance cost
161
106
110
90
62
54
Profit before tax
3,290
3,493
4,038
5,702
6,821
5,500
Net profit (owners)
2,389
2,547
2,833
4,122
5,273
3,879
EPS (₹)
29.82
31.19
34.71
51.01
65.29
48.03
Exceptional items, total income and EBITDA are read from the filed statements.
Quarterly Financials ₹ cr
Metric
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
6,678
6,604
6,163
6,694
7,051
7,073
6,730
6,957
7,589
7,074
6,541
7,119
Other Income
176
-10
249
160
191
222
289
259
269
-70
148
211
Expenses
4,944
4,856
4,847
4,978
5,165
5,084
5,192
5,179
5,695
5,819
5,586
5,927
EBITDA
—
—
—
—
—
—
—
—
—
—
—
1,189
Depreciation
290
233
288
247
272
280
309
253
297
278
383
304
Finance cost
26
30
18
18
15
15
14
14
13
14
13
17
Profit before tax
1,594
1,474
1,259
1,611
1,789
1,916
1,504
1,770
1,854
893
707
1,082
Net Profit
1,155
1,068
932
1,175
1,305
1,575
1,214
1,292
1,353
674
543
786
EPS
14.01
13.08
11.63
14.58
16.13
19.45
15.13
16.06
16.73
8.37
6.87
9.77
Balance Sheet ₹ cr, annual
Item
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Equity Capital
161
161
161
161
162
162
Reserves
18,165
20,680
23,246
26,545
31,032
34,270
Net worth
—
—
—
26,706
31,193
34,432
Borrowings
2,014
1,056
803
560
92
258
Trade receivables
—
—
—
—
5,506
5,620
Inventory
—
—
—
—
5,642
6,597
Trade payables
—
—
—
—
2,837
3,230
Current assets
—
—
—
—
23,249
24,146
Current liabilities
—
—
—
—
5,484
7,014
Net block
9,516
9,683
9,160
4,642
4,814
5,587
CWIP
969
766
1,093
1,153
1,566
2,042
Investments
2,710
2,551
3,662
5,449
7,933
8,223
Cash & equivalents
—
—
—
8,267
589
1,018
Total Assets
24,855
26,857
29,300
32,533
37,387
42,496
Cash Flow ₹ cr
Line
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash from operations
3,755
3,326
3,238
4,134
5,005
4,134
Capital expenditure
—
—
—
—
—
1,974
Cash from investing
-2,374
-1,858
-2,376
-2,982
-3,682
-2,234
Cash from financing
-1,240
-1,600
-958
-1,200
-1,293
-1,234
Free cash flow
2,964
2,645
2,102
2,819
3,490
928
Net change in cash
141
-132
-97
-49
30
473
Cash from operations is the number profit has to answer to. Free cash flow is what remains after the business pays for its own growth.
From the filings, calls & disclosures
The part no one reads — pulled from the annual report, auditor's report, concall and deck. This is the moat.
Risk register & disputes (3)
NPPA issued demand notices seeking recovery of alleged overcharging under Drugs (Prices Control) Orders 1995.
Income tax demands under appeal following reassessment orders for AY2015-16 to AY2023-24 post February 2023 Survey/Search action.
US FDA issued Form 483 with one observation at InvaGen NY facility in July 2026; Indore facility awaiting reinspection.
Audit & governance
Opinionunmodified
AuditorWalker Chandiok & Co LLP
Guidance & forward view
Operating EBITDA Margin18.50-20.00 percent FY2027
US Business Exit Run RateUSD 1000.00 million (~$1 billion) Q4 FY2027
Narrative vs numbers
US sales of $162 million in Q1 indicates a slowdown in North American growth trajectory.
Clarified by management
Segment intelligence
Segment PBIT (₹ cr)
The latest earnings call
Jun 2026 · 2026-07-23
Cipla Limited reported Q1 FY2027 consolidated revenue of ₹7,119.00 crore, up 2% YoY, marking its highest-ever first-quarter revenue. The One India business grew 12% YoY driven by chronic and respiratory therapies. Operating EBITDA margin stood at 16.7%, compressed by front-loaded operating expenses for upcoming US product launches, Middle East war freight inflation (1-2% of revenue), and accounting reclassifications of marketing spend as revenue reductions. Management reaffirmed its target of a $1 billion exit run-rate in North America by Q4 FY2027, backed by generic Ventolin scaling, three major respiratory launches, and a complex peptide pipeline, while maintaining full-year EBITDA margin guidance at 18.5% to 20.0%.
Q1 FY2027 revenue reached ₹7,119.00 crore with One-India business expanding 12% YoY.
EBITDA margin stood at 16.7% due to launch OPEX, Middle East war freight inflation, and accounting reclassification.
Reaffirmed $1 billion US exit run-rate target for Q4 FY2027 driven by complex respiratory filings and peptides.
Net cash position exceeds ₹9,494.00 crore providing strong capital for organic capex, biosimilars, and M&A.
How the tone changed
Confident in mid-term respiratory launch visibility while transparent about transient Q1 cost and freight headwinds.
The analyst grilling
Where analysts pressed management, and how they answered.
The tough questions (8)
Requested clarification on the accounting change reclassifying marketing expenditures as revenue reductions and its impact on growth rates.
Ashish Adukia explained that effective April 1, 2026, marketing spend reduces revenue; adjusted overall growth rate is ~4% instead of reported 2%.
Questioned whether the $1 billion US exit run-rate guidance is realistic given Q1 US revenue was only $162 million.
Achin Gupta confirmed line of sight driven by generic Ventolin scale-up, three major respiratory filings, and one large complex peptide launch.
Queried why South Africa reported revenue declined in rupee terms despite favorable currency movements.
Ashish Adukia noted the decline stems from losing a lower-margin tender, while the private market outpaced market growth at 6.5%.
Inquired about the reason behind sequential gross margin dip and inventory write-off magnitude.
Ashish Adukia attributed it to product mix, higher-than-normal one-time inventory write-offs, and 1-2% Middle East war cost impact.
Asked about capital allocation priorities for the $1+ billion net cash balance.
Ashish Adukia detailed priorities as increased organic capex, R&D for biosimilars, in-licensing upfronts, and targeted M&A in US/Europe.
Inquired whether the US InvaGen NY Form 483 observation will delay major upcoming launches.
Achin Gupta clarified InvaGen produces solid orals and does not affect the three major respiratory filings which are filed from inspected sites.
Queried if Q1 EBITDA margin dipping to 16.7% indicates a loss of profitability in the US business post-Revlimid.
Ashish Adukia clarified 16.7% is a transit phase due to committed launch OPEX ahead of revenue, transient war freight costs, and timing of PLI incentives.
Asked whether the upcoming large peptide product launch is subject to patent litigation or court stays.
Achin Gupta confirmed patent litigation is not a constraint and the product can launch immediately upon US FDA approval.
Money owed, promised and moved inside the group
Contingent liabilities
₹2,721 cr in total across 5 disclosed items — 7.9% of net worth. Individual items answer what; the total answers how exposed.
DPCO Overcharging Alleged Demands₹2,011 cr · 5.8% of net worth
Excise Duty / Service Tax Valuation Claims₹359 cr · 1.0% of net worth
Income Tax Disallowed Additions₹212 cr · 0.61% of net worth
Claims Against Company Not Acknowledged as Debt₹138 cr · 0.40% of net worth
Sales Tax Credit & Classification₹1.55 cr
Related-party transactions
₹7 cr transacted — approvals are a ceiling, not a spend.
CounterpartyNatureAmountStatus
Veritas Legal Entity where Non-Executive Director Abhijit Joshi is Founding & Managing PartnerLegal services fees—Transacted
GoApptiv Private Limited Associate companyPurchase of goods₹0 crTransacted
Stempeutics Research Private Limited Associate companyPurchase of goods₹7 crTransacted
Disclosure & evidencewhat the filings actually show
These are coverage counts, not ratings. Each one asks a fixed set of questions of the filings and reports how many the company answered. A company that discloses nothing counts nothing here — that is a statement about the disclosure, not about the business.
Governance
3 of 3 disclosedweighted 7 of 7
What was looked for
Unmodified audit opinion — Unmodified
CARO remarks contained — none
Board majority independent — 50% independent
Capital discipline
4 of 4 disclosedweighted 10 of 10
What was looked for
Profit converts to cash — 1.21× over 12 years
Free cash flow not persistently negative — 0 of 12 years negative
Capital converts into revenue — capital +41% vs revenue +24%
Interest comfortably covered — 102.11×
Sustainability
0 of 5 disclosedNothing disclosed on this
What was looked for
Assured reporting — not assured
Targets quantified — 0 of 1 targets quantified
Scope 3 disclosed — not disclosed
Capex tied to targets — no capex tied to targets
Externally assessed — 0 external assessments
Future readiness
1 of 3 disclosedweighted 3 of 8
What was looked for
Spend disclosed — no spend disclosed
Deployments with outcomes — 2 of 2 with a measurable outcome
Visible in operating metrics — narrative only
Others in Healthcare
The same read, applied to the companies this one competes with.
?1 question to ask7 of 19 checks ran · from the quarterly statements; filing read not yet in
Revenue₹7,119 cr▲ 2.3%on the year▲ 8.8%on the quarter
EBITDA₹1,192 cr▼ 33.0%on the yearmargin 16.7% (−881 bps)
Net profit₹786 cr▼ 39.2%on the year▲ 44.8%on the quarter
EPS₹9.77▼ 39.2%on the year
What changed
Revenue ₹7,119 cr, +2.3% on the year (this quarter has averaged +4.8% over the last 2 years); EBITDA margin 16.7%, −881 bps.
Part of the profit growth came from outside the business: reported −39.2%, core −42.4%. Other income, exceptional items or tax added 3 points.
Operating margin fell sharply on the year. Pricing, input costs, or mix? EBITDA margin 16.7%, −881 bps on the year (+214 bps on the quarter).
The quarter, explainedfrom the quarterly statements
Cipla Ltd. reported revenue of ₹7,119 cr for April to June 2026, +2.3% on the year and +8.8% on the quarter. That is in line with how this quarter has grown in recent years (+4.8% on average). Over the last four quarters revenue comes to ₹28,323 cr, +1.8% on the four before.
Operating profit (EBITDA) was ₹1,192 cr, a margin of 16.7%, −881 bps on the year and +214 bps on the quarter. Over the last 8 quarters the margin has ranged from 14.6% to 28.1%, averaging 22.2%. Operating costs grew +14.4%, faster than revenue at +2.3%, so operating profit grew less than sales.
Net profit was ₹786 cr, −39.2% on the year and +44.8% on the quarter, with earnings per share of ₹9.77. Profit before other income, one-offs and tax fell 42.4%, so 3 points of the headline growth came from outside the core business. The tax rate of 27% is in line with its recent average. Profit over the last four quarters totals ₹3,356 cr, −37.7% on the four before.
On earnings per share of ₹41.74 over the last four quarters, the stock at ₹1,321.60 trades at 31.7 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
Questions to askeach one with its numbers and source
?Question
Operating margin fell sharply on the year. Pricing, input costs, or mix?
EBITDA margin 16.7%, −881 bps on the year (+214 bps on the quarter).
Source: Quarterly statements
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Where the profit change came fromJun '25 → Jun '26
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
DISCLAIMER: FinMinutes is a financial data and analytics platform, not a registered investment adviser. Everything here is for educational and informational purposes. Forensic interpretations are computed from disclosed data and are not recommendations. Do your own due diligence.